Illexcor Therapeutics, LLC
Publicly observedRichmond, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Richmond | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Illexcor Therapeutics, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | GFKZPH9N1VX3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jan 2021Publicly observed
NIH SBIR/STTR award: Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
USD 798,351.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Aug 2020Publicly observed
NIH SBIR/STTR award: Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy
USD 529,259.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.